Ampio Pharmaceuticals (NYSE:AMPE) and Graybug Vision (NASDAQ:GRAY) Financial Contrast

Volatility and Risk

Graybug Vision has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500. Comparatively, Ampio Pharmaceuticals has a beta of 5.57, indicating that its share price is 457% more volatile than the S&P 500.

Valuation & Earnings

This table compares Graybug Vision and Ampio Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Graybug Vision	$426.96 million	0.02	-$35.60 million	($24.23)	-0.24
Ampio Pharmaceuticals	N/A	N/A	-$8.63 million	($11.01)	-0.02

Ampio Pharmaceuticals has lower revenue, but higher earnings than Graybug Vision. Graybug Vision is trading at a lower price-to-earnings ratio than Ampio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Graybug Vision and Ampio Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Graybug Vision	N/A	-77.61%	-71.34%
Ampio Pharmaceuticals	N/A	N/A	N/A

Institutional and Insider Ownership

49.9% of Graybug Vision shares are held by institutional investors. Comparatively, 5.7% of Ampio Pharmaceuticals shares are held by institutional investors. 7.9% of Graybug Vision shares are held by company insiders. Comparatively, 3.3% of Ampio Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Ampio Pharmaceuticals beats Graybug Vision on 6 of the 9 factors compared between the two stocks.

About Graybug Vision

Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.

About Ampio Pharmaceuticals

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.